ERBB2 and breast carcinoma: Her-2, is an oncogene and is overexpressed and/or amplified in approximately 30% of patients with breast carcinoma (Slamon et al., 1987), and is related to increased aggressiveness, a higher recurrence rate and mortality (Romond, 2005).